- Home
- AMLX
as 02-21-2025 4:00pm EST
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 481.9M | IPO Year: | 2022 |
| Target Price: | $7.60 | AVG Volume (30 days): | 736.4K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $19.95 | Next Earning Date: | 03-04-2025 |
| Revenue: | $196,485,000 | Revenue Growth: | -33.22% |
| Revenue Growth (this year): | -76.48% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Amylyx Pharmaceuticals Inc. (AMLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Feb 3 '25 | Sell | $3.47 | 11,851 | $41,107.56 | 3,201,247 | |
| Mazzariello Gina | AMLX | Chief Legal Officer | Feb 3 '25 | Sell | $3.49 | 3,678 | $12,839.16 | 139,090 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Feb 3 '25 | Sell | $3.47 | 11,855 | $41,103.66 | 3,164,933 | |
| Cohen Joshua B | AMLX | Co-Chief Executive Officer | Jan 6 '25 | Sell | $4.05 | 7,471 | $30,232.15 | 3,201,247 | |
| Klee Justin B. | AMLX | Co-Chief Executive Officer | Jan 6 '25 | Sell | $4.04 | 7,471 | $30,201.52 | 3,164,933 | |
| Bedrosian Camille L | AMLX | Chief Medical Officer | Dec 2 '24 | Sell | $5.54 | 5,421 | $30,007.40 | 138,380 |
Latest Amylyx Pharmaceuticals Inc. News
AMLX Breaking Stock News: Dive into AMLX Ticker-Specific Updates for Smart Investing
Business Wire
12 days ago
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Simply Wall St.
17 days ago
February 2025's Promising Penny Stocks On US Exchanges
Zacks
22 days ago
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock?
BioPharma Dive
a month ago
Intellia makes progress on HAE study; 2 more China drug deals
MT Newswires
a month ago
Amylyx Pharmaceuticals Says FDA Lifts Clinical Hold on Phase 1 ALS Study
Business Wire
a month ago
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
MT Newswires
a month ago
Amylyx Pharmaceuticals Prices $60 Million Common Stock Offering
Business Wire
a month ago
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Compare AMLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMLX Amylyx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.